Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BCAB BioAtla Inc
- Stocks
- Healthcare
- NASDAQ: BCAB
Price (delayed)
$0.4396
Market cap
$21.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
-$10.45M
BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms.
Highlights
BCAB's debt has shrunk by 71% YoY and by 34% QoQ
The company's EPS has surged by 51% YoY and by 15% QoQ
The equity has dropped by 99% year-on-year and by 96% since the previous quarter
BioAtla's quick ratio has shrunk by 52% YoY and by 40% QoQ
Key stats
What are the main financial stats of BCAB
Market
Valuations
Earnings
Shares outstanding
48.59M
Market cap
$21.36M
Enterprise value
-$10.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
46.93
Price to sales (P/S)
2.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.95
Revenue
$11M
Gross profit
$11M
Operating income
-$67.1M
Net income
-$61.88M
EBIT
-$61.88M
EBITDA
-$61.01M
Free cash flow
-$57.4M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$0.99
Book value per share
$0.01
Revenue per share
$0.19
TBVPS
$0.66
Total assets
$38.29M
Total liabilities
$37.74M
Debt
$554,000
Equity
$547,000
Working capital
$21.53M
Debt to equity
1.01
Current ratio
2.35
Quick ratio
2.02
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
-554.6%
Gross margin
100%
Net margin
-562.5%
Operating margin
-610%
Return on assets
-111.7%
Return on equity
-357.9%
Return on invested capital
N/A
Return on capital employed
-277.7%
Return on sales
-562.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCAB stock price
How has the BioAtla stock price performed over time
Intraday
1.71%
1 week
-7.51%
1 month
45.23%
1 year
-83.35%
YTD
-25.64%
QTD
26.76%
Financial performance
How have BioAtla's revenue and profit performed over time
Revenue
$11M
Gross profit
$11M
Operating income
-$67.1M
Net income
-$61.88M
Gross margin
100%
Net margin
-562.5%
BioAtla's net income has increased by 48% YoY and by 11% QoQ
BCAB's operating income is up by 46% YoY and by 9% from the previous quarter
BCAB's net margin is up by 11% QoQ
The operating margin has increased by 9% since the previous quarter
Price vs fundamentals
How does BCAB's price correlate with its fundamentals
Growth
What is BioAtla's growth rate over time
Valuation
What is BioAtla stock price valuation
P/E
N/A
P/B
46.93
P/S
2.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.95
The company's EPS has surged by 51% YoY and by 15% QoQ
The equity has dropped by 99% year-on-year and by 96% since the previous quarter
Efficiency
How efficient is BioAtla business performance
The company's return on equity has shrunk by 155% YoY and by 52% QoQ
BioAtla's ROA has decreased by 27% YoY and by 9% from the previous quarter
The company's return on sales rose by 11% QoQ
Dividends
What is BCAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCAB.
Financial health
How did BioAtla financials performed over time
The company's total assets has shrunk by 57% YoY and by 27% QoQ
BioAtla's quick ratio has shrunk by 52% YoY and by 40% QoQ
The equity has dropped by 99% year-on-year and by 96% since the previous quarter
BCAB's debt has shrunk by 71% YoY and by 34% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.